Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 11,419 matching trials from the live ClinicalTrials.gov search.
Conditions
Peritonitis
Interventions
duration of antibiotics
Other
Lead sponsor
University of Virginia
Other
Eligibility
16 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 17 more
Conditions
Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma, Rhabdoid Tumor of the Kidney, Stage I Renal Cell Cancer, Stage I Renal Wilms Tumor, Stage II Renal Cell Cancer, Stage II Renal Wilms Tumor, Stage III Renal Cell Cancer, Stage III Renal Wilms Tumor, Stage IV Renal Cell Cancer, Stage IV Renal Wilms Tumor
Interventions
Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery, Cyclophosphamide, Etoposide, Carboplatin, Dactinomycin, Vincristine Sulfate, Radiation Therapy, Laboratory Biomarker Analysis
Drug · Procedure · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
161
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 127 more
Conditions
Localized Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Best Practice, Dietary Intervention, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
5,487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
168
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 140 more
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 35 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Terminated Phase 1Phase 2 Interventional Results available

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

NCT02928029
Conditions
Multiple Myeloma
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington
Conditions
Bladder Cancer
Interventions
Hexaminolevulinate hydrochloride (HCL), Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Drug · Device
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
4,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Conditions
Depression, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Collaborative care, Interview or Focus Group, Media/technology Intervention with collaborative care, Survey Administration
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
4
States / cities
Auburn, Washington • Gig Harbor, Washington • Seattle, Washington + 1 more
Conditions
Cystic Fibrosis
Interventions
VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort B: paridiprubart, Cohort B: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Conditions
Chronic Graft Versus Host Disease
Interventions
Biospecimen Collection, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Gainesville, Florida • Tampa, Florida • Boston, Massachusetts + 6 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

NCT04623086
Conditions
Type 1 Diabetes
Interventions
Insulin Degludec, Insulin Glargine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
Interventions
TAK-186
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Conditions
Rheumatoid Arthritis
Interventions
Observational study
Other
Lead sponsor
CARE ARTHRITIS LTD.
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York + 1 more
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
alemtuzumab GZ402673
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,062 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
52
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Conditions
Urothelial Carcinoma
Interventions
disitamab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
158
States / cities
Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Tibulizumab Dose A, Tibulizumab Dose B, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more
Completed Phase 3 Interventional Results available

A Study in Second Line Metastatic Colorectal Cancer

NCT01183780
Conditions
Colorectal Cancer
Interventions
Ramucirumab, Placebo, Irinotecan, Folinic Acid, 5-Fluorouracil
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
92
States / cities
Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more
Conditions
Low-grade Glioma
Interventions
DAY101
Drug
Lead sponsor
Karen D. Wright, MD
Other
Eligibility
1 Year to 25 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Conditions
Melanoma (Skin)
Interventions
aldesleukin, filgrastim, recombinant interferon alfa, cisplatin, dacarbazine, vinblastine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
94
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Bosutinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
20
States / cities
Phoenix, Arizona • Tempe, Arizona • Sacramento, California + 11 more
Conditions
Episodic Migraine
Interventions
Standard of Care (SOC) Migraine Preventive Medication, Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
112
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
Conditions
Prostate Cancer
Interventions
tarenflurbil, adjuvant therapy
Drug · Procedure
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
58
States / cities
Homewood, Alabama • Anchorage, Alaska • Fresno, California + 49 more
Conditions
Neuroblastoma
Interventions
aldesleukin, therapeutic autologous lymphocytes, chemotherapy, ganciclovir
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington